Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 2/2016

Open Access 01-06-2016 | Review

Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET

Author: Jin Su Kim

Published in: Nuclear Medicine and Molecular Imaging | Issue 2/2016

Login to get access

Abstract

Monoclonal antibodies (mAbs), which play a prominent role in cancer therapy, can interact with specific antigens on cancer cells, thereby enhancing the patient’s immune response via various mechanisms, or mAbs can act against cell growth factors and, thereby, arrest the proliferation of tumor cells. Radionuclide-labeled mAbs, which are used in radioimmunotherapy (RIT), are effective for cancer treatment because tumor associated-mAbs linked to cytotoxic radionuclides can selectively bind to tumor antigens and release targeted cytotoxic radiation. Immunological positron emission tomography (immuno-PET), which is the combination of PET with mAb, is an attractive option for improving tumor detection and mAb quantification. However, RIT remains a challenge because of the limited delivery of mAb into tumors. The transport and uptake of mAb into tumors is slow and heterogeneous. The tumor microenvironment contributed to the limited delivery of the mAb. During the delivery process of mAb to tumor, mechanical drug resistance such as collagen distribution or physiological drug resistance such as high intestinal pressure or absence of lymphatic vessel would be the limited factor of mAb delivery to the tumor at a potentially lethal mAb concentration. When α-emitter-labeled mAbs were used, deeper penetration of α-emitter-labeled mAb inside tumors was more important because of the short range of the α emitter. Therefore, combination therapy strategies aimed at improving mAb tumor penetration and accumulation would be beneficial for maximizing their therapeutic efficacy against solid tumors.
Literature
1.
Erdi AK, Erdi YE, Yorke ED, Wessels BW. Treatment planning for radio-immunotherapy. Phys Med Biol. 1996;41:2009–26.CrossRefPubMed
2.
3.
4.
Gopal AK, Gooley TA, Rajendran JG, Pagel JM, Fisher DR, Maloney DG, et al. Myeloablative 131I-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥60 years with B cell lymphoma. Biol Blood Marrow Transplant. 2014;206:770–5.CrossRef
5.
Becker W, Behr T. High dose radioimmunotherapy in relapsed B-cell lymphoma with 131I-rituximab. Ann Hematol. 2001;80 Suppl 3:B130–1.PubMed
6.
Kang GW, Kang HJ, Shin DY, Gu HR, Choi HS, Lim SM. Radioimmunotherapy with 131I-rituximab in a patient with diffuse large B-cell lymphoma relapsed after treatment with 90Y-Ibritumomab tiuxetan. Nucl Med Mol Imaging. 2013;47:281–4.CrossRefPubMedPubMedCentral
7.
Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004;48:289–96.PubMed
8.
Jang BS, Lee SM, Kim HS, Shin IS, Razjouyan F, Wang S, et al. Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab. Nucl Med Biol. 2012;39:472–83.CrossRefPubMedPubMedCentral
9.
Wang S, Shin IS, Hancock H, Jang BS, Kim HS, Lee SM, et al. Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. J Control Release. 2012;20(162):218–24.CrossRef
10.
Boerman OC, Oyen WJ. Immuno PET of cancer: a revival of antibody imaging. J Nucl Med. 2011;52:1171–2.CrossRefPubMed
11.
van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379–89.CrossRefPubMed
12.
13.
Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, et al. 64Cu DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013;54:1869–75.CrossRefPubMed
14.
Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, et al. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu DOTA-trastuzumab PET. J Nucl Med. 2014;55:23–9.CrossRefPubMedPubMedCentral
15.
Braghirolli AM, Waissmann W, da Silva JB, dos Santos GR. Production of 124I and its applications in nuclear medicine. Appl Radiat Isot. 2014;90:138–48.CrossRefPubMed
16.
Preylowski V, Schlogl S, Schoenahl F, Jorg G, Samnick S, Buck AK, et al. Is the image quality of 124I PET impaired by an automatic correction of prompt gammas? PLoS One. 2013;27(8):e71729.CrossRef
17.
Lee YS, Kim JS, Kim H-J, Woo S-K, Kim JG, Park JA, et al. Imaging Characteristics of 124I Between 3D and 2D on Siemens ECAT HR PET Scanner. IEEE Trans Nucl Sci. 2013;60:797–801.CrossRef
18.
Kim JS, Yu AR. Determination of single gamma photon fraction of 124I PET. J Instrum. 2015;10(P03006):1–8.
19.
Yu AR, Kim JS. Effect of filters and reconstruction algorithms on 124I PET in Siemens Inveon PET scanner. J Instrum. 2015;10(P10026):1–12.
20.
Yu AR, Kim JS, Kang JH, Lim SM. Comparison of reconstruction methods and quantitative accuracy in Siemens Inveon PET scanner. J Instrum. 2015;10(P04001):1–16.
21.
Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with 89Zr for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739–43.CrossRefPubMed
22.
Borjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, et al. Performance of immuno PET with 89Zr chimeric mAb U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133–40.CrossRefPubMed
23.
Sugyo A, Tsuji AB, Sudo H, Nagatsu K, Koizumi M, Ukai Y, et al. Evaluation of 89Zr labeled human anti-CD147 mAb as a PET probe in a mouse model of pancreatic cancer. PLoS One. 2013;8:e61230.CrossRefPubMedPubMedCentral
24.
Lee YS, Kim JS, Kim JY, Kim BI, Lim SM, Kim HJ. Spatial resolution and image qualities of 89Zr on Siemens Biograph TruePoint PET/CT. Cancer Biother Radiopharm. 2015;30:27–32.CrossRefPubMedPubMedCentral
25.
Disselhorst JA, Brom M, Laverman P, Slump CH, Boerman OC, Oyen WJ, et al. Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med. 2010;51:610–7.CrossRefPubMed
26.
Quackenbush RC, Horner TJ, Williams VC, Giampietro P, Lin TS. Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and 131I tositumomab. Leuk Lymphoma. 2015;56:779–81.CrossRefPubMed
27.
Srinivasan A, Mukherji SK. Tositumomab and 131I tositumomab (Bexaar). AJNR Am J Neuroradiol. 2011;32:637–8.CrossRefPubMed
28.
Sjogreen-Gleisner K, Dewaraja YK, Chiesa C, Tennvall J, Linden O, Strand SE, et al. Dosimetry in patients with B-cell lymphoma treated with 90Y ibritumomab tiuxetan or 131I tositumomab. Q J Nucl Med Mol Imaging. 2011;55:126–54.PubMed
29.
Hohloch K, Lankeit HK, Zinzani PL, Scholz CW, Lorsbach M, Windemuth-Kieselbach C, et al. Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. Eur J Nucl Med Mol Imaging. 2014;41:1585–92.CrossRefPubMed
30.
Andrade Campos MM, Montes Limon AE, Grasa JM, Lievano P, Baringo T, Giraldo P. RIT with 90Y-ibritumomab tiuxetan in follicular non-Hodgkin lymphoma: evaluation of recent outcomes in a single institution. J Oncol. 2012;2012:412742.CrossRefPubMedPubMedCentral
31.
Prasad V. The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab. JAMA Intern Med. 2014;174:1887–8.CrossRefPubMed
32.
Frost SH, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, et al. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. PLoS One. 2015;18(10):e0120561.CrossRef
33.
Attarwala AA, Molina-Duran F, Busing KA, Schonberg SO, Bailey DL, Willowson K, et al. Quantitative and qualitative assessment of 90Y PET/CT imaging. PLoS One. 2014;4(9):e110401.CrossRef
34.
Lhommel R, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Bilbao JI, et al. 90Y TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging. 2009;36:1696.CrossRefPubMed
35.
Rong X, Du Y, Frey EC. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to 90Y bremsstrahlung SPECT imaging. Phys Med Biol. 2012;21(57):3711–25.CrossRef
36.
de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu and 90Y labeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:13S–7.PubMed
37.
Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med. 1994;35:152–6.PubMed
38.
Lu Y, Ndjock N, Mbong G, Liu P, Chan C, Cai Z, et al. Synthesis of polyglutamide-based metal-chelating polymers and their site-specific conjugation to trastuzumab for auger electron radioimmunotherapy. Biomacromolecules. 2014;9(15):2027–37.CrossRef
39.
Li HK, Morokoshi Y, Daino K, Furukawa T, Kamada T, Saga T, et al. Transcriptomic signatures of auger electron radioimmunotherapy using nuclear targeting 111In-trastuzumab for potential combination therapies. Cancer Biother Radiopharm. 2015;30:349–58.CrossRefPubMed
40.
Baranowska-Kortylewicz J. Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors. Immunotherapy. 2011;3:491–4.CrossRefPubMed
41.
Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, et al. Intravesical alpha-radioimmunotherapy with 213Bi anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009;50:1700–8.CrossRefPubMed
42.
Back T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, et al. Glomerular filtration rate after alpha-radioimmunotherapy with 211At MX35-F(ab’)2: a long-term study of renal function in nude mice. Cancer Biother Radiopharm. 2009;24:649–58.CrossRefPubMed
43.
Lucignani G. Alpha-particle radioimmunotherapy with 211At and 213Bi. Eur J Nucl Med Mol Imaging. 2008;35:1729–33.CrossRefPubMed
44.
Zhang M, Yao Z, Zhang Z, Garmestani K, Talanov VS, Plascjak PS, et al. The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res. 2006;66:8227–32.CrossRefPubMed
45.
Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 2009;69:8941–8.CrossRefPubMedPubMedCentral
46.
Kiess AP, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC, et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen. J Nucl Med. 2015;56:1401–7.CrossRefPubMedPubMedCentral
47.
Gardette M, Viallard C, Paillas S, Guerquin-Kern JL, Papon J, Moins N, et al. Evaluation of two 125I radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma. Investig New Drugs. 2014;32:587–97.CrossRef
48.
Falzone N, Fernandez-Varea JM, Flux G, Vallis KA. Monte Carlo evaluation of auger electron-emitting theranostic radionuclides. J Nucl Med. 2015;56:1441–6.CrossRefPubMed
49.
Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;19(22):1879–903.CrossRef
50.
51.
Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53:1310–25.CrossRefPubMedPubMedCentral
52.
Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and 131I tositumomab. Semin Oncol. 2003;30:31–8.CrossRefPubMed
53.
Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med. 2005;46:840–9.PubMedPubMedCentral
54.
Lee YS, Kim JS, Cho KD, Kang JH, Lim SM. Tumor dosimetry for 131I trastuzumab therapy in a Her2+ NCI N87 xenograft mouse model using the Siemens SYMBIA E gamma camera with a pinhole collimator. J Instrum. 2015;10(P07001):1–10.
55.
Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P, et al. Dose escalation and dosimetry of first-in-human alpha radioimmunotherapy with 212Pb TCMC-trastuzumab. J Nucl Med. 2014;55:1636–42.CrossRefPubMedPubMedCentral
56.
Miller BW, Frost SH, Frayo SL, Kenoyer AL, Santos E, Jones JC, et al. Quantitative single-particle digital autoradiography with alpha-particle emitters for targeted radionuclide therapy using the iQID camera. Med Phys. 2015;42:4094–105.CrossRefPubMed
57.
Miller BW, Gregory SJ, Fuller ES, Barrett HH, Barber HB, Furenlid LR. The iQID camera: an ionizing-radiation quantum imaging detector. Nucl Instrum Methods Phys Res Sect A. 2014;11(767):146–52.CrossRef
58.
Frost SH, Miller BW, Back TA, Santos EB, Hamlin DK, Knoblaugh SE, et al. Alpha imaging confirmed efficient targeting of CD45-positive cells after 211At radioimmunotherapy for hematopoietic cell transplantation. J Nucl Med. 2015;56:1766–73.CrossRefPubMedPubMedCentral
59.
Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29:57–61.PubMedPubMedCentral
60.
Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421–34.CrossRefPubMedPubMedCentral
61.
Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 2007;48:995–9.CrossRefPubMed
62.
Thurber GM, Weissleder R. Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels. Mol Imaging Biol. 2011;13:623–32.CrossRefPubMedPubMedCentral
63.
64.
65.
Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–54.CrossRefPubMed
66.
67.
Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806–13.CrossRefPubMed
68.
Heine M, Freund B, Nielsen P, Jung C, Reimer R, Hohenberg H, et al. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One. 2012;7:e36258.CrossRefPubMedPubMedCentral
69.
Choi IK, Strauss R, Richter M, Yun CO, Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol. 2013;26(3):193.
70.
Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, Yumul R, et al. Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther. 2011;19:479–89.CrossRefPubMedPubMedCentral
71.
Du Y, Honeychurch J, Glennie M, Johnson P, Illidge T. Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma. Cancer Res. 2007;67:1335–43.CrossRefPubMed
72.
Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med. 2005;46 Suppl 1:141S–50.PubMed
73.
Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, et al. Fractionated radioimmunotherapy with 90Y clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer. 2012;118:5497–506.CrossRefPubMedPubMedCentral
74.
Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–34.CrossRefPubMed
75.
Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, et al. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther. 2013;12:48–57.CrossRefPubMedPubMedCentral
76.
Na Y, Choi JW, Kasala D, Hong J, Oh E, Li Y, et al. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model. J Control Release. 2015;220(Pt B):766–82.CrossRefPubMed
77.
Vogel KG, Paulsson M, Heinegard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J. 1984;223:587–97.CrossRefPubMedPubMedCentral
78.
Khaibullina A, Jang BS, Sun H, Le N, Yu S, Frenkel V, et al. Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J Nucl Med. 2008;49:295–302.CrossRefPubMed
Metadata
Title
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET
Author
Jin Su Kim
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 2/2016
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-015-0392-7

Other articles of this Issue 2/2016

Nuclear Medicine and Molecular Imaging 2/2016 Go to the issue

Review

Instrumentation for Time-of-Flight Positron Emission Tomography

Original Article

A Comparison Study of Esophageal Findings on 18F-FDG PET/CT and Esophagogastroduodenoscopy

Editorial

Start from Scratch: the Prospect of Nuclear Cardiology

Original Article

Clinical Value of a One-Stop-Shop Low-Dose Lung Screening Combined with 18F-FDG PET/CT for the Detection of Metastatic Lung Nodules from Colorectal Cancer

Original Article

Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody

Interesting Image

18F-FDG PET/CT for Detecting Sarcoma of the Aorta in a Patient with Takayasu Arteritis